Acute miliary tuberculosis of a single specified site
ICD-10 A19.0 is a billable code used to indicate a diagnosis of acute miliary tuberculosis of a single specified site.
Acute miliary tuberculosis is a disseminated form of tuberculosis characterized by the presence of numerous small lesions resembling millet seeds in the lungs and other organs. This condition arises when Mycobacterium tuberculosis spreads through the bloodstream, leading to a systemic infection. In cases classified under A19.0, the acute miliary tuberculosis is localized to a single specified site, which may include the lungs, liver, or spleen. Clinically, patients may present with fever, night sweats, weight loss, and respiratory symptoms. Diagnosis typically involves a combination of clinical evaluation, imaging studies such as chest X-rays or CT scans, and microbiological tests including sputum smear and culture. Treatment usually consists of a multi-drug regimen, often including isoniazid, rifampin, pyrazinamide, and ethambutol, and requires careful monitoring for drug resistance and adverse effects. Public health considerations are paramount, as miliary tuberculosis can be highly contagious, necessitating contact tracing and isolation protocols to prevent further transmission.
Detailed clinical notes including symptoms, diagnostic tests, and treatment plans.
Patients presenting with respiratory symptoms and a history of exposure to tuberculosis.
Need for thorough documentation of drug resistance testing and treatment response.
Pulmonary function tests, imaging results, and treatment protocols.
Patients with acute respiratory distress and suspected miliary tuberculosis.
Importance of documenting any co-existing lung conditions.
Used to evaluate suspected miliary tuberculosis.
Radiology report must be included in the patient's medical record.
Pulmonologists should ensure that imaging findings correlate with clinical symptoms.
Common diagnostic tests include sputum smear and culture, chest X-rays, CT scans, and blood tests for TB infection.
Treatment typically involves a multi-drug regimen including isoniazid, rifampin, pyrazinamide, and ethambutol, with careful monitoring for drug resistance.
Public health measures include contact tracing, isolation of infected individuals, and monitoring for outbreaks.
